Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Inclusion Criteria: * Females at least 18 years of age with ovarian carcinoma who are one of the following: * Newly diagnosed with ovarian cancer and chemotherapy naïve, or * Post a single previous course of chemotherapy, with a 3-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit, or * Post two or more previous courses of chemotherapy with a 6-month disease-progression and treatment-free interval, with the exception of antibody therapy, prior to the study screening visit. * Must be scheduled for a course of combination chemotherapy consisting of gemcitabine and cisplatin or gemcitabine and carboplatin to be administered in 21-day cycles * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Adequate bone marrow, renal, and hepatic functions as measured by standard chemistry and hematology blood tests * Adequate blood coagulation parameters as measured by standard blood tests for coagulation Exclusion Criteria: * Any clinical or laboratory abnormality greater than Grade 2 toxicity (NCI criteria), with the exception of laboratory parameters specified in the inclusion criteria * Significant unstable cardiovascular disease * Uncontrolled high blood pressure * Current use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II antagonists * Evidence of metastatic disease to the bone * Metastatic disease to the CNS requiring treatment or radiation therapy …